PATENT COOPERATION TREATY

Mmu DR OFV.

From the INTERNATIONAL SEARCHING AUTHORITY			_	. PCI				
PFIZER RESEARCH AND DEVELOPMENT Actn. Wood, David J. Lamsgate Road Eandwich Cent CT13 9NJ INITED KINGDOM 1 6 MAY 2005		NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL SEARCH REPORT AND THE WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY, OR THE DECLARATION (PCT Rule 44.1) Date of mailing (day/month/year) 17/05/2005						
			ᆜ	1	17/05	/2005		
Applicant's or agent's file refe PC25833A	erence	anni die e nature a sere		FOR FURTI	HER ACTION	See paragraphs 1 a	nd 4 below	
International application No.				International f				
PCT/IB2005/000221				(day/month/y	$\frac{ear}{26/01}$	2005		
			_ 	55 /			_	
		1.0						
PFIZER PRODUCTS I	inc.	412	C)5 /	<u> </u>	TLING		
. []	eby notified that the intern		_			DEBITNOIS		
The applicant is her Authority have been	reby notified that the interr n established and are tran	national se: smitted he	arci rew	h report and the	written opinion of the	International Search	ling	
Filing of amendms	ints and statement unde	r Article 1	g.		ļ			
The applicant is ent	itted, if he so wishes, to a	mend the c	lair					
	e limit for filing such amer tional Search Report; how							
Where? Directly to	•	•		=	•	Janying Sheet.		
Whater Directly to	the international Burea 1211 Geneva 20,	Switzerland	, 5 I, F	ascimile No.: (4	1–22) 740.14.35			
For more detailed	instructions, see the not	es on the a	1000	ompanying shee	ot.			
	reby notified that no internat effect and the written o							
3. With regard to the	protest against paymen	t of (an) ad	diti	ional fee(s) u nd e	er Rule 40.2, the appli	cant is notified that:		
applicant's red	gether with the decision the quest to forward the texts as been made yet on the p	of both the	pro	otest and the de	cision thereon to the	designated Offices.	e i	
4. Reminders								
Shortly after the expiration of 18 months from the priority date, the international application will be published by the international Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the international Bureau as provided in Rules 90 bis.1 and 90 bis.3, respectively, before the completion of the technical preparations for international publication.								
International Bureau. The International preliminary	It comments on an informa e International Bureau will examination report has be the expiration of 30 monti	send a copen or is to	py o	of such commen established. The	its to all designated O	ffices unless an		
examination must be filed date (in some Offices evi	he priority date, but only in dif the applicant wishes to en later); otherwise, the a tional phase before those	postpone pplicant mu	the ust,	e entry into the n , within 20 mont	ational phase until 30	months from the p	orionity	
In respect of other design	nated Offices, the time lim	it of 30 mo	nt	hs (or later) will	apply even if no dem	and is filed within 19)	
See the Annex to Form F	PCT/IB/301 and, for details al Chapters and the WIP(nits, Office by Office, s	see the PCT Applica	nnt's	
Name and mailing address of	of the International Search	ing Author	itv	Authorized of	fficer			
l •	nt Office, P.B. 5818 Paten	_	*y	1				
NL-2280 HV RI	ijswijk 40-2040, Tx. 31 651 epo			Josef	Ullrich			

NOTES TO FORM PCT/ISA/220

These Notes are intended to give the basic instructions concerning the filing of amendments under article 19. The Notes are based on the requirements of the Patent Cooperation Treaty, the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the PCT Applicant's Guide, a publication of WIPO.

In these Notes, "Article", "Rule", and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative Instructions respectively.

INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international search report, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the international preliminary examination procedure, there is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before international publication. Furthermore, it should be emphasized that provisional protection is available in some States only.

What parts of the international application may be amended?

Under Article 19, only the claims may be amended.

During the international phase, the claims may also be amended (or further amended) under Article 34 before the International Preliminary Examining Authority. The description and drawings may only be amended under Article 34 before the International Examining Authority.

Upon entry into the national phase, all parts of the international application may be amended under Article 28 or, where applicable, Article 41.

When?

Within 2 months from the date of transmittal of the international search report or 16 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the International Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Rule 46.1).

Where not to file the amendments?

The amendments may only be filed with the international Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been its filed, see below.

How?

Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed.

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required, in all cases where claims are renumbered, they must be renumbered consecutively (Administrative Instructions, Section 205(b)).

The amendments must be made in the language in which the international application is to be published.

What documents must/may accompany the amendments?

Letter (Section 205(b)):

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confused with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

The letter must be in English or French, at the choice of the applicant. However, if the language of the international application is English, the letter must be in English; if the language of the international application is French, the letter must be in French.

Notes to Form PCT/ISA/220 (first sheet) (January 1994)

NOTES TO FORM PCT/ISA/220 (continued)

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) the claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new:
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

The following examples illustrate the manner in which amendments must be explained in the accompanying latter:

- [Where originally there were 48 claims and after amendment of some claims there are 51]:
 "Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers;
 claims 30, 33 and 36 unchanged; new claims 49 to 51 added."
- [Where originally there were 15 claims and after amendment of all claims there are 11]: "Claims 1 to 15 replaced by amended claims 1 to 11."
- [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims;
 Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added or
 - "Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added." or "Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."
- 4. [Where various kinds of amendments are made]: "Claims 1-10 unchanged; claims 11 to 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claim 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added."

"Statement under article 19(1)" (Rule 46.4)

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

it must be in the language in which the international appplication is to be published.

It must be brief, not exceeding 500 words if in English or if translated into English.

It should not be confused with and does not replace the latter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It may not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

Consequence if a demand for international preliminary examination has already been filed

If, at the time of filing any amendments under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the same time of filing the amendments with the International Bureau, also file a copy of such amendments with the International Preliminary Examining Authority (see Rule 62.2(a), first sentence).

Consequence with regard to translation of the international application for entry into the national phase

The applicant's attention is drawn to the fact that, where upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see Volume II of the PCT Applicant's Guide

Notes to Form PCT/ISA/220 (second sheet) (January 1994)

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference	FOR FURTHER	see Form PCT/ISA/220				
PC25833A	ACTION	as well as, where applicable, Item 5 below.				
International application No.	International filing date (day/month)	/year) (Earliest) Priority Date (day/month/year)				
PCT/IB2005/000221	26/01/2005	02/02/2004				
Applicant						
PFIZER PRODUCTS INC.						
This International Search Report has been according to Article 18. A copy is being tra		ching Authority and is transmitted to the applicant				
This international Search Report consists of a total of sheets.						
X It is also accompanied by	a copy of each prior art document cit	ted in this report.				
	international search was carried out o	on the basis of the international application in the em.				
The international this Authority (Ru		of a translation of the international application furnished to				
	• "	disclosed in the international application, see Box No. I.				
2. Certain claims were fou	2. Certain claims were found unsearchable (See Box II).					
3. Unity of invention is lac	3. Unity of invention is lacking (see Box III).					
4. With regard to the title,						
x the text is approved as su	bmitted by the applicant.					
the text has been establis	shed by this Authority to read as follow	ws:				
5. With regard to the abstract,	inmitted by the englished					
	the text is approved as submitted by the applicant. the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box No. IV. The applicant					
		tional search report, submit comments to this Authority.				
6. With regard to the drawings ,						
a. the figure of the drawings to be	published with the abstract is Figure I	No				
as suggested by	• •					
· = ·	is Authority, because the applicant fa	•••				
1 <u> </u>	is Authority, because this figure bette se published with the abstract	er characterizes ine invention.				
b. X none of the figures is to t	e published with the abstract.	•				

International Application No PCT/IB2005/000221

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C07D453/02

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) IPC $\frac{7}{100}$ C070

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BEILSTEIN Data, CHEM ABS Data

C. DOCUM	ENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of t	the relevant passages	Relevant to claim No
A	WO 97/03984 A (PFIZER INC; TIC L; MELTZ, MORGAN) 6 February 1997 (1997-02-06) page 8, line 5; claims 1,6 page 8 - page 9	CKNER, DEREK,	1-10
A	US 6 222 038 B1 (ITO FUMITAKA 24 Apr11 2001 (2001-04-24) cited in the application column 5, line 6 - column 6, example 1 column 7, last paragraph		1-10
X Furt	ther documents are listed in the continuation of box C.	Patent family members are	Isted in annex.
Special of A docum consider E earlier filing of L docum which cliatio O docum other P docum	ategories of cited documents : ent defining the general state of the art which is not derect to be of particular relevance document but published on or after the international	"T' later document published after the or priority date and not in conflicted to understand the principle invention." "X' document of particular relevance cannot be considered novel or involve an inventive step when "Y" document of particular relevance cannot be considered to involve document is combined with one ments, such combination being in the art. "&" document member of the same parts such combination to the same parts.	e international filing date at with the application but or theory underlying the the claimed invention annot be considered to the document is taken alone the claimed invention an inventive step when the or more other such docu- obvious to a person skilled
Special care of the course of the clatte of the Cate o	ategories of cited documents: sent defining the general state of the art which is not dered to be of particular relevance document but published on or after the international date ent which may throw doubts on priority datin(s) or a sciled to establish the publication date of another on or other special reason (as specified) entering to an oral disclosure, use, exhibition or means ent published prior to the international filing date but than the priority date claimed	*T' tater document published after the or priority date and not in conflict cited to understand the principle invention. *X' document of particular relevance cannot be considered novel or involve an inventive step when document of particular relevance cannot be considered to involve document is combined with one ments, such combination being in the art.	e international filing date of with the application but or theory underlying the it he claimed invention annot be considered to the document is taken alone it he claimed invention an inventive step when the or more other such docu- obvious to a person skilled valent family
Special care of the country of the clation of the care	ategories of cited documents: sent defining the general state of the art which is not dered to be of particular relevance document but published on or after the International date ent which may throw doubts on priority claim(s) or a sciled to establish the publication date of another on or other special reason (as specified) the referring to an oral disclosure, use, exhibition or means sent published prior to the international filing date but than the priority date claimed	*T' later document published after the or priority date and not in conflict cited to understand the principle invention. *X' document of particular relevance cannot be considered novel or involve an inventive step when the cannot be considered to involve document to combined with one ments, such combination being in the art. *&' document member of the same page of mailing of the internation.	e international filing date of with the application but or theory underlying the it he claimed invention annot be considered to the document is taken alone it he claimed invention an inventive step when the or more other such docu- obvious to a person skilled valent family

1

International Application No
PCT/IB2005/000221

		PC1/1B2009	37 000221
C.(Continu	ation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category •	Citation of document, with indication, where appropriate, of the relevant passages		Relevant to claim No.
A	WARAWA E J ET AL: "Quinuclidine chemistry. 4. Diuretic properties of cis-3-amino-2-benzhydrylquinuclidine." JOURNAL OF MEDICINAL CHEMISTRY. JUN 1975, vol. 18, no. 6, June 1975 (1975-06), pages 587-593, XP002327149 ISSN: 0022-2623 Scheme 1 page 587		1-10
A	US 6 255 320 B1 (QUALLICH GEORGE JOSEPH ET AL) 3 July 2001 (2001-07-03) cited in the application claims 1,8		9
Ρ,Α	WO 2004/035575 A (PFIZER PRODOUCTS, INC; DSM PHARMACEUTICALS, INC; NUGENT, THOMAS, C; SE) 29 April 2004 (2004-04-29) cited in the application page 3, last paragraph; examples page 3, line 1 - line 4		1-10

1

Information on patent family members

International Application No
PCT/IB2005/000221

					05/000221
Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 9703984	Α	06-02-1997	AT	250600 T	15-10-2003
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	•••		AU	697553 B2	08-10-1998
			AU	6134896 A	18-02-1997
			CA	2227194 A1	06-02-1997
			CN	1190970 A ,C	19-08-1998
			CZ	9800150 A3	17-02-1999
			DE	69630123 D1	30-10-2003
			DE	69630123 T2	08-04-2004
			DK	840735 T3	09-02-2004
			EP	0840735 A1	13-05-1998
			ES	2205039 T3	01-05-2004
			HK	1010195 A1	16-11-2001
			HU	9900238 A2	28-05-1999
					06-02-1997
			WO	9703984 A1	
			JP	3043074 B2	22-05-2000
			JP	10511102 T	27-10-1998
			NO	980211 A	16-03-1998
			NZ	310539 A	25-11-1998
			PL	324610 A1	08-06-1998
			PT	840735 T	27-02-2004
			RU	2136681 C1	10-09-1999
			US	6008357 A	28-12-1999
			ZA 	9606026 A	16-01-1998
US 6222038	B1	24-04-2001	AP	299 A	14-01-1994
	•		AT	135006 T	15-03-1996
			AU	657552 B2	16-03-1995
			AU	1990192 A	08-01-1993
			BG	61694 B1	31-03-1998
			BG	98248 A	15-07-1994
			BR	9206073 A	06-12-1994
			CA	2102179 A1	01-12-1992
			CN	1067428 A ,C	30-12-1992
			CZ	9203906 A3	16-02-1994
			DE	9290063 U1	24-02-1994
			DE	69208877 D1	11-04-1996
			DE	69208877 T2	25-07-1996
			DK	587723 T3	01-04-1996
			EG	19944 A	27-02-1997
			EΡ	0587723 A1	23-03-1994
			ES	2084361 T3	01-05-1996
			FI	935297 A	29-11-1993
			GR	3019687 T3	31-07-1996
			HU	70151 A2	28-09-1995
			ΙE	921729 A1	02-12-1992
			IL	102008 A	08-12-1995
			JР	2645225 B2	25-08-1997
			JP JP	2645225 B2 7285965 A	31-10-1995
			JP JP JP	2645225 B2 7285965 A 7033386 B	31-10-1995 12-04-1995
			JP JP JP JP	2645225 B2 7285965 A 7033386 B 6504292 T	31-10-1995 12-04-1995 19-05-1994
			JP JP JP	2645225 B2 7285965 A 7033386 B	31-10-1995 12-04-1995 19-05-1994 02-08-1999
			JP JP JP JP	2645225 B2 7285965 A 7033386 B 6504292 T	31-10-1995 12-04-1995 19-05-1994
			JP JP JP JP KR	2645225 B2 7285965 A 7033386 B 6504292 T 214905 B1	31-10-1995 12-04-1995 19-05-1994 02-08-1999
			JP JP JP KR MA	2645225 B2 7285965 A 7033386 B 6504292 T 214905 B1 22539 A1	31-10-1995 12-04-1995 19-05-1994 02-08-1999 31-12-1992
			JP JP JP KR MA MX NO	2645225 B2 7285965 A 7033386 B 6504292 T 214905 B1 22539 A1 9202554 A1	31-10-1995 12-04-1995 19-05-1994 02-08-1999 31-12-1992 01-11-1992
			JP JP JP KR MA MX NO NZ	2645225 B2 7285965 A 7033386 B 6504292 T 214905 B1 22539 A1 9202554 A1 934312 A	31-10-1995 12-04-1995 19-05-1994 02-08-1999 31-12-1992 01-11-1992 29-11-1993
			JP JP JP KR MA MX NO	2645225 B2 7285965 A 7033386 B 6504292 T 214905 B1 22539 A1 9202554 A1 934312 A 242956 A	31-10-1995 12-04-1995 19-05-1994 02-08-1999 31-12-1992 01-11-1992 29-11-1993 27-06-1995

information on patent family members

International Application No
PCT/IB2005/000221

					·
Patent document cited in search report		Publication date		Patent family member(s)	Publication date
US 6222038	B1		PT	100546 A	,B 31-08-1993
			RO	110499 B1	
			RU	2103269 C1	
			SK	390692 A3	
			WO	9221677 A1	
			ÜS	5807867 A	15-09-1998
			US	5939433 A	17-08-1999
			ZA	9203942 A	29-11-1993
US 6255320	B1	03-07-2001	AT	244239 T	15-07-2003
			AU	767334 B2	
	1		AU	4424800 A	18-12-2000
	•		BG	106204 A	31-07-2002
			BR	0011094 A	19-03-2002
			CA	2372238 A1	
			CN	1353711 A	,C 12-06-2002
			CZ	20014269 A3	3 17-04-2002
			DE	60003679 DI	07-08-2003
			DE	60003679 T2	27-05-2004
			DK	1181290 T3	3 29-09-2003
			EA	3731 B1	l 28-08-2003
			EE	200100656 A	17-02-2003
			EP	1181290 A	l 27-02-2002
			ES	2199825 T3	
			HK	1046284 A	
			HR	20010904 A	
			HU	0201301 A2	
			WO	0073304 A	
			JP	2003501354 T	14-01-2003
			ΜX	PA01012325 A	22-07-2002
			NO	20015848 A	18-12-2001
			NZ	515349 A	26-03-2004
			PL	352716 A	
			PT	1181290 T	30-09-2003
			SI	1181290 T	
			SK	17332001 A	
			TR	200103473 T	
			ZA	200109775 A	28-11-2002
W0 2004035575	 A	29-04-2004	AU	2003277353 A	1 04-05-2004
WO 2004035575	A	29-04-2004	AU WO	2003277353 A 2004035575 A	

PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHORITY To: WRITTEN OPINION OF THE see form PCT/ISA/220 INTERNATIONAL SEARCHING AUTHORITY (PCT Rule 43bis.1) Date of mailing (day/month/year) see form PCT/ISA/210 (second sheet) Applicant's or agent's file reference FOR FURTHER ACTION see form PCT/ISA/220 See paragraph 2 below International application No. International filing date (day/month/year) Priority date (day/month/year) 02.02.2004 PCT/B2005/000221 26.01.2005 International Patent Classification (IPC) or both national classification and IPC C07D453/02 Applicant PFIZER PRODUCTS INC. This opinion contains indications relating to the following items: Box No. I Basis of the opinion ☐ Box No. II Priority Non-establishment of opinion with regard to novelty, inventive step and industrial applicability Box No. III Box No. IV Lack of unity of invention Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement Box No. VI Certain documents cited Box No. VII Certain defects in the international application Box No. VIII Certain observations on the international application 2. **FURTHER ACTION** If a demand for international preliminary examination is made, this opinion will usually be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA"). However, this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notifed the International Bureau under Rule 66.1 bis(b) that written opinions of this International Searching Authority will not be so considered. If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of three months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later. For further options, see Form PCT/ISA/220. For further details, see notes to Form PCT/ISA/220. **Authorized Officer** Name and mailing address of the ISA:

Härtinger, S

Telephone No. +49 89 2399-8289

Form (PCT/ISA/237) (Cover Sheet) (January 2004)

European Patent Office

Fax: +49 89 2399 - 4465

Tel. +49 89 2399 - 0 Tx: 523656 epmu d

D-80298 Munich

\$107709089

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/IB2005/000221

	Maria de la Caración
Box No. I Basis of	the opinion
With regard to the lar the language in which	nguage, this opinion has been established on the basis of the international application in it was filed, unless otherwise indicated under this item.
☐ This opinion has language , wh. (under Rules 12.	been established on the basis of a translation from the original language into the following ich is the language of a translation furnished for the purposes of international search 3 and 23.1(b)).
	ucleotide and/or amino acid sequence disclosed in the international application and med invention, this opinion has been established on the basis of:
a. type of material:	
☐ a sequence li	sting
□ table(s) relate	ed to the sequence listing
b. format of material:	
☐ in written form	nat
☐ in computer r	eadable form
c. time of filing/furnish	ning:
contained in t	the international application as filed.
☐ filed together	with the international application in computer readable form.
☐ furnished sub	esequently to this Authority for the purposes of search.
has been filed or	e case that more than one version or copy of a sequence listing and/or table relating theret r furnished, the required statements that the information in the subsequent or additional al to that in the application as filed or does not go beyond the application as filed, as re furnished.
4. Additional comments): :

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/IB2005/000221

Box No. V Reasoned statement under Rule 43*bis*.1(a)(l) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)

Yes: Claims

1-10

No: Claims

Inventive step (IS)

Yes: Claims

1-10

No: Claims

Industrial applicability (IA)

Yes: Claims

1-10

No: Claims

2. Citations and explanations

see separate sheet

Box No. Vi Certain documents cited

 Certain published documents (Rules 43bis.1 and 70.10) and /or

2. Non-written disclosures (Rules 43bis.1 and 70.9)

see form 210

iAP20 Rec'd PUT/FTO 01 AUG 2006

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY (SEPARATE SHEET)

International application No.

PCT/IB2005/000221

Re Item V:

 The application relates to a process for preparing camphersulfonic acid (CSA) salt of 1-(2S,3S)-2-Benzhydryl-N-(5-ter-butyl-2-methoxybenzyl)quinuclidin-3-amine having the formula lb. The process makes use of intermediates in the CSA salt form, of which the preferred intermediate Via is likewise claimed.

The relevant prior art is represented by the following documents.

- D1: WO 97/03984 A (PFIZER INC; TICKNER, DEREK, L; MELTZ, MORGAN) 6 February 1997 (1997-02-06)
- D2: US-B1-6 222 038 (ITO FUMITAKA ET AL) 24 April 2001 (2001-04-24)
- D3: WARAWA E J ET AL: "Quinuclidine chemistry. 4. Diuretic properties of cis-3-amino-2-benzhydrylquinuclidine." JOURNAL OF MEDICINAL CHEMISTRY. JUN 1975, vol. 18, no. 6, June 1975 (1975-06), pages 587-593, XP002327149 ISSN: 0022-2623
- D4: US-B1-6 255 320 (QUALLICH GEORGE JOSEPH ET AL) 3 July 2001 (2001-07-03)

The cited prior art makes use of CSA in catalytic amounts to achieve the amination of 3-ketoquinuclidine. CSA has also been used for the resolution of racemic end-products. While enatiomerically pure cis-intermediates of the type presently used are known in the art, none of the cited documents discloses CSA quinuclidine salts, which were pulled through a multi-step synthesis procedure. By consequence, the claimed processes and intermediate (VIa) appear to be novel in the sense of Art. 33(2) PCT.

The most pertinent prior art is represented by D1, D2 and D3. D1 teaches the use of CSA for the resolution of racemic 2-Benzhydryl-N-(5-iso-propyl-2-methoxybenzyl)quinuclidin-3-amine. The said resolution step only occurs at the end of the multi-step procedure and does not involve the transformation of CSA intermediates. While the use of enatiomeric intermediates, such as 2-Benzhydryl-N-benzyl)quinuclidin-3-amine and 2-Benzhydryl-quinuclidin-3-amine, are suggested for the production of 2S,3S-cis end products (eg. page 8 of D1), the use of intermediates in salt form is not taught. Similarly, the documents D2 and D3 teach, that

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY (SEPARATE SHEET)

International application No.

PCT/IB2005/000221

enatiomerically pure cis-intermediates may be pulled through analogous multi-step procedures, whereby the enantiomers have been obtained by chromatography or by formation with chiral acids at the final synthesis step. The skilled person, who was looking to find an alternative process for the synthesis of known product (I), was therefore left without guidance, when solving the problem by the use of the present CSA quinuclidine intermediates (VIa) and (VII). The claimed processes and the intermediates, which are essential for proposed solution, are therefore considered to be the result of not obvious modifications of the prior art. The claimed subject-matter appears therefore to meet the requirement of Art. 33(3) PCT.

Re Item VI:

1. The international patent application D5 (= WO 2004/035575 A, PFIZER PRODOUCTS, INC; DSM PHARMACEUTICALS, INC; NUGENT, THOMAS, C; SE, 2004-04-29) has been published between the priority and filing date of the present application. The free amino intermediates and the CSA salt of final products disclosed therein do therefore not form part of the state of the art as defined in the PCT. By consequence, D5 has been disregarded from further considerations.

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

□ BLACK BORDERS
□ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
□ FADED TEXT OR DRAWING
□ BLURRED OR ILLEGIBLE TEXT OR DRAWING
□ SKEWED/SLANTED IMAGES
□ COLOR OR BLACK AND WHITE PHOTOGRAPHS
□ CRAY SCALE DOCUMENTS
□ LINES OR MARKS ON ORIGINAL DOCUMENT

IMAGES ARE BEST AVAILABLE COPY.

☐ OTHER:

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY